Skip to Content
 

Venture Capital and Entrepreneurship Panel

“Creating and Managing Innovative Technology-Driven Companies that Address Unmet Medical and System Needs”

ISSUES

  • Examples of novel technologies and systems enhancements (life science and healthcare services/IT) venture capital firms are currently supporting focused on improving health outcomes and reducing healthcare costs.
  • Challenges VC firms are facing in today’s regulatory and economic environment – available exit options and expected returns.
  • Best practices in identifying, evaluating, and negotiating new venture investments, including key inflection points to maximize value.
  • Lessons learned by “serial entrepreneurs” in creating and managing early-stage life science and healthcare services companies, including working with VCs and Angel investors, capital formation, and partnership strategies.


David Tamburri
Partner
Health Enterprise Partners

David is a General Partner with Health Enterprise Partners, L.P. (HEP), a growth equity fund focused exclusively on healthcare services and information technology companies.  Prior to joining HEP, David was a VP with Susquehanna Growth Equity, a private equity group focused on growth capital opportunities in the technology sector. He was formerly the President and COO at Onward Healthcare, Inc., a provider of human capital services to healthcare providers sponsored by Welsh, Carson, Anderson, & Stowe.  As an EVP with Pinnacor, Inc., a provider of information and analytical applications, David managed the company’s worldwide operations. Pinnacor completed an IPO in 2000 and was later sold to CBS Marketwatch.

David is on the boards of eVariant, Privia Health, and Summetria. He is a board observer at MDx Medical. He was a director of MobileMD prior to the company's sale to Siemens. He serves on the Advisory Board of the NYC Health Business Leaders and on the board of The Open Door Shelter. Since 2000, David has been a Lecturer at Columbia University in the Executive Master of Science in Technology Management program.

He is a distinguished graduate of the United States Military Academy and holds an MBA from Harvard Business School.

Jeff Butler
Chairman and Chief Executive Officer
Privia Health

Jeff Butler, Founder, President and CEO, PriviaHealth, has an extensive background as an entrepreneur and senior executive in the healthcare industry. Before creating Privia Health, he was Founder and CEO of BroadReach Healthcare, a company focused on creating large-scale health delivery networks in emerging markets. In less than 5 years, Jeff led BroadReach to become a widely recognized leader in global health, including securing a $100 million contract from the US Government to implement an innovative private sector HIV/AIDS treatment and disease management program in South Africa. Under Mr. Butler's leadership, BroadReach conducted engagements and partnerships with such organizations as The Bill & Melinda Gates Foundation, Merck, Virgin, McKinsey & Co, Harvard University, the Government of China, the World Bank, and the United Nations.

Prior to BroadReach, Jeff served as Director at The Advisory Board Company (NASDAQ: ABCO) – a healthcare research, consulting firm, and think tank representing over 2,500 hospital, pharmaceutical, and medical device member institutions. At the Advisory Board, Jeff helped to develop and manage a strategy consulting practice assisting hospitals and healthcare organizations. Previous to The Advisory Board, he served as a hospital COO, Interim CEO for two hospitals, and as one of the founding team members for the start-up and $900 million public spin-off of LifePoint Hospitals (NASDAQ: LPNT) from HCA (NYSE: HCA).

John Crowley
Chairman and Chief Executive Officer
Amicus Therapeutics

John Crowley is Chairman, President & CEO of Amicus Therapeutics, based in Cranbury, N.J.  Amicus is a 130-person publicly-held biotechnology company working on the development of drugs to treat a range of human genetic diseases. 

Previously he was founding president and CEO of Orexigen Therapeutics, and SVP at Genzyme Therapeutics, a position he assumed after overseeing the sale of Novazyme Pharmaceuticals to Genzyme in 2001. Mr. Crowley was the founding president and CEO of Novazyme that was developing a novel treatment for Pompe disease. He also served in several senior management roles with Bristol-Myers Squibb.

John’s involvement in the biotechnology industry stems from the 1998 diagnosis of his two youngest children, Megan and Patrick, with Pompe disease: a rare and fatal neuromuscular disorder.   Crowley embarked on his journey as an entrepreneur to find a treatment that would save his kids’ lives – and the lives of thousands of others. The Crowley family’s journey has been chronicled in The Wall Street Journal, in the book by Pulitzer prize winning author Geeta Anand, The Cure, and in the 2010 motion picture:  Extraordinary Measures” starring Harrison Ford and Brendan Fraser.

Mr. Crowley is a commissioned officer in the US Naval Reserve assigned to the US Special Operations Command, with service in Afghanistan.  He is on the national board of directors of the Make-a-Wish Foundation. 

Mr. Crowley earned his B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, his J.D. from the University of Notre Dame Law School and his M.B.A. from Harvard Business School.

Gur Roshwalb, MD
Vice President 
Venrock Equity Funds
 

Gur joined Venrock in 2008. Previously, he was a vice president and senior research analyst at Piper Jaffray & Co., focusing on specialty pharmaceuticals and small cap biotech companies. In this role, Gur was responsible for analyzing, valuing and publishing research on both publicly traded and privately held biotech and specialty pharmaceutical companies. Gur was trained in internal medicine at the Mount Sinai Medical Center, New York, where he also served as chief resident, and subsequently spent several years in private practice as an internist in New York.

Gur received his B.A. from Columbia University, M.B.A. from Leonard N. Stern School of Business and M.D. from Albert Einstein College of Medicine.

Elizabeth Stoner, MD
Managing Director
MPM Capital

Dr. Elizabeth Stoner joined MPM in 2007 as Managing Director, following a 22-year career at Merck Research Laboratories. She is also Chief Development Officer for Rhythm Pharmaceuticals.

At the time of her retirement from Merck, she was Senior Vice President, Global Clinical Development Operations with responsibility for the company's clinical development activities in more than 40 countries. She also oversaw the clinical development activities of Merck's Japanese partner Banyu,led the clinical development for the Merck/Schering-Plough Joint Venture for Zetia/Vytorin, and played a critical leadershiprole in efforts to transform Merck’s worldwide clinical development operations.

Previously, she led the Proscar clinical development program from inception, establishing Merck as a leader in the field of prostate disease. As Endocrine Therapeutic Head, Dr. Stoner's responsibilities included all steroid and lipid metabolism, as well as the growth hormone secretagogue clinical research programs.

Prior to Merck, she was an Assistant Professor of Pediatrics, Cornell University Medical College.

Dr. Stoner received a B.S. in Chemistry from Ottawa University, KS, an M.S. in Chemistry, State University of New York at Stony Brook; an M.D. from Albert Einstein College of Medicine.

She serves on the boards of Momenta Pharmaceuticals and Radius Health.